The company has reached its 100th peer-reviewed publication highlighting the clinical potential of Parsortix. Earnings call discussions include details on deals with AstraZeneca, Recursion pilot study, sales strategy, resource management, and collaborations with NuProbe.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing